Wednesday, 3 March 2021

COVAXIN shows interim efficacy of 81% against coronavirus in Phase 3 clinical trials, says Bharat Biotech


via Firstpost Tech Latest News https://ift.tt/2MGpWD9

post written by:

Related Posts

0 comments: